Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context

Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with microsatellite stable/mismatch repair-proficient met...

Descripción completa

Detalles Bibliográficos

Autores principales:	Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2023-04-01
Colección:	EClinicalMedicine
Materias:	Regorafenib Nivolumab Microsatellite stable Mismatch repair-proficient Metastatic colorectal cancer
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2589537023000949
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!